Royalty Pharma Buys an Interest in Fumaderm for $761 Million
Royalty Pharma recently announced it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash. The Fumapharm earn-out primarily represents an indirect interest in Biogen Idec’s BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of relapsing-remitting multiple sclerosis (RRMS). The earn-out also includes an interest in Fumaderm, a therapeutic approved in
Recently, Biogen Idec presented positive data on BG-12 from the Phase III CONFIRM trial, the second positive Phase III study of BG-12 in the treatment of RRMS, at the 64th Annual Meeting of the
“We are pleased to acquire an interest in one of the most promising new therapies addressing the needs of patients with relapsing-remitting multiple sclerosis,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. “The combination of efficacy, safety, and tolerability of BG-12 shown in the DEFINE and CONFIRM Phase III trials, the oral dosing regimen and Biogen Idec’s deep commitment to this disease category, leads us to believe that BG-12 has blockbuster potential.”
“The management and shareholders of Fumapharm AG deserve credit for identifying this breakthrough therapy that has the potential to improve the lives of thousands of patients with relapsing-remitting multiple sclerosis,” Mr. Legorreta added. “We are also pleased to have been able to offer the former Fumapharm shareholders an opportunity to realize immediate liquidity for a portion of their interest in the Fumapharm earn-out, and to mitigate the risks associated with owning such a concentrated financial asset.”
Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late-stage biopharmaceutical products, with royalty interests in 30 products valued at over $7 billion. Royalty Pharma has a 16-year history of providing value to royalty holders, including its $400-million purchase of 80% of Memorial Sloan-Kettering Cancer Center’s Neupogen/Neulasta royalty, its $700-million acquisition of AstraZeneca’s Humira royalty, its $700-million purchase of a portion of Northwestern University’s Lyrica royalty, its $650-million purchase of NYU’s Remicade royalty, its joint $525-million acquisition with Gilead Sciences of Emory University’s emtricitabine royalty, and most recently its $609-million acquisition of Astellas’ patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes.
Total Page Views: 1221
